Several tumor cells secrete significantly increased amounts of the plasminogen activator urokinase, a trypsinlike serine protease, whose biological function in tumor biology is unclear. In this study we report that cells of the human epidermal tumor cell line CCL 20.2 express about 80,000 high-affinity urokinase receptors per cell that bind active as well as diisopropylfluorophosphate-treated high-molecular-weight (HMW) urokinase. Low-molecular-weight (LMW) urokinase is not bound to the receptor. Occupation of these receptors by active HMW urokinase stimulates cell proliferation independently in the presence of plasminogen in the culture medium. LMW urokinase has again no effect on cell proliferation. Calculated on a molar basis, this effect is about 28% of that of epidermal growth factor. Active HMW urokinase might therefore provide an autocrine receptor-mediated growth-promoting mechanism for tumor cells similar to those described for other growth factors.
Plasma levels of urokinase-type plasminogen activator have been investigated in 80 patients with prostatic carcinoma by means of a radioimmunoassay. A total of 30 patients with disseminated prostatic carcinoma had significantly elevated levels of urokinase-type plasminogen activator, whereas the plasma levels in patients without metastases did not differ from a healthy age matched control group. Sensitivity of elevated urokinase-type plasminogen activator levels in patients with prostatic carcinoma for the presence of metastases was 80 per cent. Therefore, urokinase-type plasminogen activator appears to be a reliable marker for the formation of metastases in prostatic carcinoma.
Binding of urokinase-type plasminogen activator (u-PA) to its receptor has been shown not only to focus proteolytic activity to the cell surface but also to exert a mitogenic effect on the human epidermal tumor cell line CCL 20.2. This report shows that u-PA is an autocrine mitogen in the human melanoma cell line GUBSB and that inhibition of receptor-bound u-PA by specific anti-u-PA antibodies causes a significant suppression of cell proliferation in this system. The GUBSB cell line secretes 70-80% of the u-PA in its active form and expresses high-affinity u-PA receptors with a Kd of 5.2 X 10-10 M and 2.8 x 104 binding sites per cell. Approximately 70% of the u-PA receptors on these cells are occupied by endogenously secreted u-PA. Addition of the monoclonal antiu-PA antibody MPW5UK (10 nM), directed against the active site of u-PA, twice daily to the cell cultures resulted in a significant decrease of [3H~thymidine incorporation by the tumor cells, whereas a 10 times higher concentration of the monoclonal antibody MPW4UK, which does not inhibit plasminogen activator activity of u-PA, was necessary to achieve the same effect. In addition, diisopropyl fluorophosphateinactivated u-PA, in a concentration 50-fold higher than the concentration necessary to saturate the u-PA receptor (250 pM), decreased [3H]thymidine incorporation similarly to the specific antibody, proving that active u-PA is required for the mitogenic effect. Inhibition of endogenous u-PA production by cycloheximide reduced [3H]thymidine incorporation significantly; after addition of exogenous u-PA, [3H]thymidine incorporation increased again in the cycloheximide-treated cells. Therefore, inhibition of receptor-bound u-PA might represent a tool not only to inactivate cell-bound proteolytic activity, necessary for invasion, but also to exert a specific antiproliferative effect on certain tumor cells.Malignant cells contain and secrete plasminogen activators (PAs; EC 3.4.21.31), trypsin-like serine proteases, to a much higher extent than their respective normal counterparts (1-3). Immunological characterization has shown that most malignant cells produce urokinase-type PA (u-PA) rather than tissue-type PA (t-PA) (2). u-PA contains not only an activesite domain consistent with its serine protease character and involved in the activation ofplasminogen but also a "kringle" domain, found in several other seine proteases, and a growth-factor domain homologous to the epidermal growth factor (4).
In this study we report on the effect of urokinase fragments on the proliferation of cells of the human epidermal cell line, CCL 20.2, which expresses high-affinity receptors for urokinase and the growth of which is stimulated by intact active 54-kDa urokinase. The 33-kDa fragment containing only the active-site domain, does not bind to the receptors and does not stimulate cell proliferation, while the 17-kDa fragment, containing only the kringle and the growth-factor domains binds to the receptor but does not stimulate growth of the human epidermal cell line. Growth promotion of this tumor cell line by urokinase is therefore restricted to the complete intact and active urokinase molecule.Activation of plasminogen to plasmin by plasminogen activators may play an important role in the invasion and formation of metastases of tumor cells [l -31. Plasmin is a degradative enzyme capable of digesting the extracellular matrix; it exerts its action either directly on glycoproteins, such as fibronectin or laminin [4,5], or indirectly by activation of latent collagenase [6]. A correlation between cancer and increased plasminogen-activator activity has been found by several groups [3, 71. Significantly elevated levels of plasminogen activator activity in extracts of primary tumors and metastases were found when compared to their normal counterparts [3, 8, 91. Immunological characterization has revealed that most malignant cells produce urokinase-type plasminogen activator (uPA) rather than tissue-type plasminogen activator (tPA) [3, 8, 91. While these data present only indirect support for the involvement of plasminogen activators in malignant processes, more direct evidence can be obtained from the following experiments. Inhibition of plasmin action by tranexamic acid reduced tumor growth of several tumor cell lines implanted into nude mice and inhibited the formation of metastases in rabbits [lo, 111. Moreover, antibodies against urokinase could be shown to inhibit the formation of metastases by a human tumor cell line in an animal model [ 121. We have found previously [ 131 that a human epidermal cell line CCL 20.2, neither containing nor secreting plasminogen activators or plasminogen-activator inhibitors, expresses high-affinity urokinase receptors, similar to those found for several other cell lines [14-161 and that active high-molecular-mass urokinase stimulates proliferation of this cell line. Mitogenic effects of fluid-phase uPA have been previously reported, however, without characterization of urokinase determinants for the observed effects [17]. To prove further that both an intact active site as well as binding of the urokinase molecule to the urokinase receptor are necessary for growth stimulation of the human epidermal tumor cell line, CCL 20.2, we compared, in the present study, the proliferative effect of intact urokinase to that of urokinase fragments. MATERIALS AND METHODS MaterialsTissue-culture cluster plates, 24 flat-bottom wells (Costar, Cambridge, MA); Tween 20, diisopropylfluorophosphate,
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.